# To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases

> **NCT05889325** · — · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Liver Metastases (CRCLM)

## Interventions

- **PROCEDURE:** DEB-TACE plus HAIC

## Key facts

- **NCT ID:** NCT05889325
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2023-09
- **Final completion:** 2023-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889325, "To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05889325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*